<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584362</url>
  </required_header>
  <id_info>
    <org_study_id>OXFEND-02, IND 113,628</org_study_id>
    <secondary_id>IND 113,628</secondary_id>
    <nct_id>NCT01584362</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Safety Study of Oxfendazole</brief_title>
  <acronym>OXFEND-02</acronym>
  <official_title>Phase I Study of Oxfendazole (Toward the Treatment of Neurocysticercosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>School of Veterinary Medicine, Universidad Nacional Mayor de San Marcos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to learn about the safety in humans of a medicine that is already
      used in cows and pigs to treat worms. The medicine may be useful for people who have these or
      other worms. The medicine will be studied first in healthy people, who will be given a very
      small amount of the medicine once. If the smallest amount of medicine is found to be safe, a
      slightly higher amount will be given to a new group of volunteers. The highest amount that
      will be tested is similar to the amount given to animals. If the medicine can be given safely
      to healthy people in the planned amounts, a later study will be done in people who have worms
      to see if the medicine kills the worms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase I study proposed is a randomized, double-blind, placebo-controlled evaluation of
      the safety and pharmacokinetics of escalating single oral doses of oxfendazole (0.3 to 30
      mg/kg) in healthy volunteers. The dose will be increased approximately three-fold (one-half
      log) at each increment, and each cohort will comprise ten volunteers (eight drug, two
      placebo). Subjects will be monitored for three weeks after dosing, including monitoring the
      pharmacokinetics and metabolism of oxfendazole in blood and urine. Each new cohort will be
      dosed only after the three week safety data for the preceding group have been analyzed. If a
      clinically significant adverse event is observed, and if this event is possibly drug-related,
      an additional (and final) cohort of volunteers will repeat the highest tolerated dose of
      oxfendazole. Up to 70 volunteers (56 drug, 14 placebo) will complete the study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    study conducted under Clinical Trials Agreement as NIAID registration NCT02234570
  </why_stopped>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serious adverse events</measure>
    <time_frame>up to three weeks after dosing</time_frame>
    <description>Proportion of patients who present with serious adverse events (SAEs) related to oxfendazole.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>up to three weeks after dosing</time_frame>
    <description>proportion of subjects who present with adverse events (AEs) related to ocfendazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>blood samples are drawn at 17 time points up to three weeks and urine is collected at 7 intervals up to 72 hours after dosing</time_frame>
    <description>The following PK parameters will be analyzed:
Maximum plasma concentration (Cmax), Time to Cmax (Tmax), Elimination rate constant (Iz), Elimination half-life (T½), Area under the curve to the final sample (AUC0-t), Area under the curve to infinity (AUC∞), Oral clearance (CL/F), Oral volume of distribution (Vz/F)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Tenia Solium Infection</condition>
  <arm_group>
    <arm_group_label>oxfendazole 0.3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of a single oral 0.3mg/kg dose of oxfendazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administration of a single oral dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxfendazole 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of a single oral 1.0 mg/kg dose of oxfendazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxfendazole 3.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of a single oral 3 mg/kg dose of oxfendazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxfendazole 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of a single oral 10 mg/kg dose of oxfendazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxfendazole 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of a single oral 20 mg/kg dose of oxfendazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxfendazole 30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of a single oral 30 mg/kg dose of oxfendazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxfendazole</intervention_name>
    <description>administration of a single oral 1.0 mg/kg dose of oxfendazole</description>
    <arm_group_label>oxfendazole 1.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single oral dose of placebo</description>
    <arm_group_label>placebo comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxfendazole</intervention_name>
    <description>administration of a single oral 3.0 mg/kg dose of oxfendazole</description>
    <arm_group_label>oxfendazole 3.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxfendazole</intervention_name>
    <description>administration of a single oral 0.3 mg/kg dose of oxfendazole</description>
    <arm_group_label>oxfendazole 0.3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxfendazole</intervention_name>
    <description>administration of a single oral 10 mg/kg dose of oxfendazole</description>
    <arm_group_label>oxfendazole 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxfendazole</intervention_name>
    <description>administration of a single oral 20 mg/kg dose of oxfendazole</description>
    <arm_group_label>oxfendazole 20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxfendazole</intervention_name>
    <description>administration of a single oral 30 mg/kg dose of oxfendazole</description>
    <arm_group_label>oxfendazole 30</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Height and weight within 25% of means for his/her gender and age.

          -  Willing to use two acceptable methods of contraception (approved oral, injectable, or
             implantable drug, IUD, diaphragm or condom with spermicidal jelly or foam, or sexual
             abstinence) for a minimum of one week before, and three weeks after dosing with
             oxfendazole; or surgically sterile.

          -  Able to give written informed consent.

          -  Able to provide a home phone number, and the name, address, and phone number of a
             person willing to assist making contact during the follow-up phase of the study.

        Exclusion Criteria:

          -  Pregnant.

          -  Breast feeding.

          -  Chronic drug/alcohol user.

          -  Has clinically significant abnormalities in screening examinations

          -  Has history of sensitivity to related benzimidazole compounds (e.g. albendazole,
             mebendazole).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert H Gilman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <results_reference>
    <citation>Gonzalez AE, Falcon N, Gavidia C, Garcia HH, Tsang VC, Bernal T, Romero M, Gilman RH. Treatment of porcine cysticercosis with oxfendazole: a dose-response trial. Vet Rec. 1997 Oct 18;141(16):420-2.</citation>
    <PMID>9364715</PMID>
  </results_reference>
  <results_reference>
    <citation>Gonzales AE, Garcia HH, Gilman RH, Gavidia CM, Tsang VC, Bernal T, Falcon N, Romero M, Lopez-Urbina MT. Effective, single-dose treatment or porcine cysticercosis with oxfendazole. Am J Trop Med Hyg. 1996 Apr;54(4):391-4.</citation>
    <PMID>8615453</PMID>
  </results_reference>
  <results_reference>
    <citation>Gonzalez AE, Falcon N, Gavidia C, Garcia HH, Tsang VC, Bernal T, Romero M, Gilman RH. Time-response curve of oxfendazole in the treatment of swine cysticercosis. Am J Trop Med Hyg. 1998 Nov;59(5):832-6.</citation>
    <PMID>9840607</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Robert Gilman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Taenia solium</keyword>
  <keyword>neurocysticercosis</keyword>
  <keyword>oxfendazole</keyword>
  <keyword>clinical trial, phase 1</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurocysticercosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxfendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

